This $173,300 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports Phagepro, P.b.c. (doing business as Phagepro Inc.), a minority-owned, woman-owned small business, in planning for a Phase I/II clinical trial of their Prophylactic-VC (PVC) bacteriophage cocktail intervention to prevent the spread of cholera. The funding will be used to develop necessary clinical trial...
This Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) is funding a $410,977 project led by Case Western Reserve University to develop methods for designing safe and effective bacteriophage (virus) cocktails to control the growth of unwanted bacteria in water systems. The 5-year project aims to: (1) identify genetic and transcriptomic markers of synergistic versus antagonistic bacteriophage cocktail interactions, and (2) assess off-target infection...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the federal Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $385,383 to the California Institute of Technology (Caltech) to develop an adaptive framework for rapidly synthesizing and reconfiguring synthetic bacterial viruses (phages) to counter antibiotic resistance. The key products and services to be delivered include:...
This $1,000,000 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Phagepro, P.b.c., a minority-owned, woman-owned small business. The grant supports the development of a prophylactic cholera phage cocktail, with a project period from December 16, 2024, to May 31, 2027. This work aims to create targeted phage interventions that can potentially reduce cholera infection rates and...
This federal Project Grant award of $714,053 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to optimize the regimen structure and characterize the pharmacokinetics and pharmacodynamics of a multi-phage (N-phage) cocktail to treat extensively drug-resistant Pseudomonas aeruginosa infections. The project proposes developing a translational assay for quantifying the N-phage cocktail, optimizing the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $112,077 to The Ohio State University to develop novel bacteriophage-based therapies to combat Pseudomonas aeruginosa and Candida species dual-species biofilms. The key objectives are to: 1) develop combination treatments using antimicrobial peptides and bacteriophages, and 2) genetically engineer P. aeruginosa...
This federal Project Grant award in the amount of $746,813.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to increase appropriate treatment of Shigella while limiting antimicrobial resistance in low-resource settings. The key objectives are to: 1) characterize the impact of inappropriately treated Shigella on diarrhea outcomes in children in Tanzania, 2) evaluate novel...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under CFDA 93.310 (Trans-NIH Research Support) provides $1,148,000.00 to The Trustees of Princeton University to develop novel approaches for combating bacterial infections and antibiotic resistance. The key products/services to be delivered include: Utilizing single-cell RNA sequencing methods (M3-SEQ and Dual-M3-SEQ) to monitor host-pathogen interactions and phage dynamics at the single-cell level,...
The University of Delaware was awarded a $2,812,558 Trans-NIH Research Support Project Grant from the National Institutes of Health Office of the Director to develop an oral vaccine delivery platform utilizing nitrated bacterial antigens displayed on Bacillus subtilis spores. The three-year project aims to advance the understanding of how nitration can enhance the immunogenicity of weakly immunogenic bacterial antigens from pathogens like Shigella. Researchers will perform animal studies using...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $479,730 to the University of Wisconsin-Madison to conduct research on how prophages (viral DNA) within probiotic gut bacteria regulate the production of antimicrobial compounds like reuterin. The overarching goal is to gain mechanistic insights into the interplay between probiotic bacteria and their prophages, and to determine the...